RhoC Upregulation Is Correlated with Reduced E-cadherin in Human Breast Cancer Specimens After Chemotherapy and in Human Breast Cancer MCF-7 Cells

Hormones and Cancer

Volumn 5, Issue 6, 2014, Pages 414-423

  Kawata, Hirotoshi ^a   Kamiakito, Tomoko ^a   Omoto, Yawara ^a   Miyazaki, Chieko ^a   Hozumi, Yasuo ^a   Tanaka, Akira ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CADHERIN; ETOPOSIDE; FIBRONECTIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN, HUMAN; TUMOR MARKER;

ACTIN FILAMENT; ADULT; AGED; BREAST NEOPLASMS; CANCER STAGING; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; UPREGULATION; VERY ELDERLY;

ACTIN CYTOSKELETON; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CADHERINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; ETOPOSIDE; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MIDDLE AGED; NEOPLASM STAGING; RHO GTP-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84938676821     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-014-0199-5     Document Type: Article

References (29)

1. The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70
2. Lee AV, Davidson NE (2013) Genomics, drug approval, and optimal treatment duration. Nat Rev Clin Oncol 11:71–72
3. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI (2006) Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 118:290–301
4. Creighton CJ, Li X, Landis M, Dixon M, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal tumor-initiating features. Proc Natl Acad Sci U S A 106:13820–13825
5. Foroni C, Broggini M, Generali D, Damia G (2012) Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 38:689–697
6. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Poylak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
7. Visvader JE, Lindeman GJ (2013) Cancer stem cells in solid tumors: accumulating evidence and unsolved questions. Nat Rev Cancer 8:755–768
8. Rahman H, Saleem M (2012) Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 30:372–378
9. Song L-B, Li J, Liao W-T, Feng Y, Yu C-P, Hu L-J, Kong Q-L, Xu L-H, Zhang X, Liu W-L, Li M-Z, Zhang L, Kang T-B, Fu L-W, Huang W-L, Xia Y-F, Tsao SW, Li M, Band V, Shi Q-H, Zeng Y-X, Zeng M-S (2006) The polycomb group protein BMI1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 119:3626–3636
10. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2:76–83
11. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia de Herreros A (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2:84–89
12. Joensuu K, Hagström J, Leidenius M, Haglund C, Andersson LC, Sariola H, Heikkilä P (2011) Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases-elevated Bmi1 expression in late breast cancer relapses. Virchow Arch 459:31–39
13. Van Nes JG, de Kruijf EM, Putter H, Faratian D, Munro A, Campbell F, Smit VT, Liefers GJ, Kuppen PJ, van de Velde CJ, Bartlett JM (2012) Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat 133:49–59
14. Kawata H, Shimada N, Kamiakito T, Komatsu K, Morita T, Ota T, Obayashi M, Shitara K, Tanaka A (2012) RhoC and guanine nucleotide exchange factor Net1 in androgen-unresponsive mouse mammary carcinoma SC-4 cells and human prostate cancer after short-term endocrine therapy. Prostate 72:1071–1079
15. Olson EN, Nordheim A (2010) Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 11:353–365
16. Heasman SJ, Ridley AJ (2008) Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 9:690–701
17. Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535
18. Shikada Y, Yoshino I, Okamoto T, Fukuyama S, Kameyama T, Maehara Y (2003) Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma. Clin Cancer Res 9:5282–5286
19. Wang W, Yang L-Y, Huang G-W, Lu W-Q, Yang Z-L, Yang J-Q, Liu H-L (2004) Genomic analysis reveals RhoC as a potent marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90:2349–2355
20. Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha H, Mak TW (2005) RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 19:1974–1979
21. van Golen KL, Wu Z-F, Qiao XT, Bao LW, Merajver SD (2000) RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60:5832–5838
22. Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu Z-F, Merajver SD (2005) RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 93:101–110
23. Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B (2005) Snail, slug, and smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103:1631–1643
24. Moody SE, Perez D, Pan T-C, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8:197–209
25. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, Kutok J, Hartwell K, Richardson AL, Weinberg RA (2007) Mesenchyme forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A 104:10069–10074
26. Zhang S, Balch C, Chan MW, Lai H-C, Matei D, Schilder JM, Yan PS, Huang TH-M, Nephew KP (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68:4311–4320
27. Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y, Song E (2011) Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 17:7105–7115
28. Kawamoto A, Yokoe T, Tanaka K, Saigusa S, Toiyama Y, Yasuda H, Inoue Y, Miki C, Kusunoki M (2012) Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep 27:51–57
29. Doublier S, Riganti C, Voena C, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A (2008) RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Mol Cancer Res 6:1607–1620